A number of other research firms also recently commented on EXEL. Leerink Swann restated a buy rating and issued a $10.00 target price on shares of Exelixis in a research report on Tuesday, July 19th. Stifel Nicolaus lifted their target price on Exelixis from $12.00 to $15.00 and gave the company a buy rating in a research report on Thursday, September 15th. Finally, Zacks Investment Research upgraded Exelixis from a hold rating to a buy rating and set a $14.00 target price on the stock in a research report on Tuesday, September 13th. Six research analysts have rated the stock with a buy rating, The stock currently has a consensus rating of Buy and an average target price of $13.51.
Shares of Exelixis (NASDAQ:EXEL) opened at 11.91 on Monday. Exelixis has a 12 month low of $3.55 and a 12 month high of $15.58. The company’s 50-day moving average price is $12.74 and its 200-day moving average price is $8.44. The company’s market cap is $2.74 billion.
Exelixis (NASDAQ:EXEL) last posted its earnings results on Wednesday, August 3rd. The biotechnology company reported ($0.16) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.27) by $0.11. The business earned $36.25 million during the quarter, compared to analysts’ expectations of $16.76 million. During the same quarter in the prior year, the firm earned ($0.22) EPS. Exelixis’s revenue for the quarter was up 353.7% compared to the same quarter last year. Equities analysts forecast that Exelixis will post ($0.61) EPS for the current fiscal year.
In related news, insider Gisela Schwab sold 42,338 shares of the company’s stock in a transaction dated Thursday, August 4th. The stock was sold at an average price of $11.00, for a total value of $465,718.00. Following the completion of the sale, the insider now directly owns 174,354 shares of the company’s stock, valued at approximately $1,917,894. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 5.90% of the stock is owned by corporate insiders.
Hedge funds have recently made changes to their positions in the stock. Farallon Capital Management LLC purchased a new stake in shares of Exelixis during the second quarter worth about $38,386,000. Janus Capital Management LLC purchased a new stake in shares of Exelixis during the second quarter worth about $25,702,000. Lord Abbett & CO. LLC purchased a new stake in shares of Exelixis during the second quarter worth about $22,690,000. Sector Gamma AS purchased a new stake in shares of Exelixis during the second quarter worth about $16,087,000. Finally, Point72 Asset Management L.P. purchased a new stake in shares of Exelixis during the second quarter worth about $15,818,000. 81.80% of the stock is owned by hedge funds and other institutional investors.
Exelixis, Inc is a biopharmaceutical company. The Company is engaged in developing small molecule therapies for the treatment of cancer. It focuses on the development and commercialization of cabozantinib, an inhibitor of multiple receptor tyrosine kinases, in various tumor indications. Cabozantinib is indicated for the treatment of progressive, metastatic medullary thyroid cancer, and is sold under the brand name COMETRIQ.
Receive News & Ratings for Exelixis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.